← Back to Home

The Era of Hepatitis D Treatment Is Approaching as Roche Moves Viral Load Testing Toward Full Automation

HDV not only needs to be detected; it also needs to be tracked consistently. The significance of cobas HDV lies in bringing a test that previously relied more heavily on manual work and laboratory-developed workflows into the routine cadence of large-scale molecular diagnostics platforms.

By SURL BioNews

Hepatitis D has long been a more dangerous offshoot in the shadow of hepatitis B: it cannot infect the human body on its own, but when the hepatitis B virus is present, it can accelerate the liver’s progression toward decompensation, cirrhosis, and liver cancer. As treatment options targeting HDV begin to appear in some markets, the clinical question is changing as well; physicians need to know not only whether a patient is infected, but also whether the viral load declines with treatment.

Roche announced on July 14 that it has launched the cobas HDV test in countries accepting the CE mark, for use on the cobas 5800, 6800, and 8800 systems. The company positions it as the first high-throughput, fully automated HDV RNA testing solution on the market, capable of detecting and quantifying hepatitis D virus RNA to support diagnosis of active infection and to track response in chronic HDV patients receiving antiviral therapy.

According to the product information, this is an in vitro diagnostic nucleic acid amplification test using human EDTA plasma or serum samples, intended for people who are HDV antibody-positive or known to be infected. Detection of HDV RNA indicates that the virus is replicating and can therefore serve as evidence of active infection; when used for treatment management, it can establish a baseline before treatment and compare changes in RNA concentration during the course of therapy.

What this product may truly change is not a single testing principle, but the testing workflow. Roche’s product page states that cobas HDV completes sample preparation, nucleic acid extraction and purification, PCR amplification, and detection on the same platform. Results can be interpreted by the system as target not detected, below the lower limit of quantitation, above the upper limit of quantitation, or a quantitative result within the linear range. For laboratories already using the cobas 5800, 6800, or 8800, the new HDV assay is expected to be easier to incorporate into existing molecular testing workflows.

This also explains why automation is especially important for HDV. Roche and industry media reports both note that HDV testing in the past was often limited by manual methods or laboratory-developed tests, making result consistency and accessibility harder to standardize. As treatment monitoring increasingly relies on changes in viral load, more stable testing across different laboratories gives clinical interpretation a more common language.

However, this remains launch news for a diagnostic tool, and does not mean HDV care has been fully solved. The announcement did not provide actual rollout countries, pricing, local reimbursement arrangements, or clinical comparison data against existing HDV tests. The product information also notes that results must be interpreted alongside other clinical and laboratory information, and that the test must be operated by trained clinical laboratory personnel. For non-CE mark markets, availability still depends on local regulatory processes and laboratory procurement timelines.

At the public health level, HDV’s particular characteristics still make hepatitis B vaccination the most fundamental means of prevention. The new automated RNA test will not replace prevention, nor will it directly treat the disease. Its role is more like making one of the most severe viral hepatitides more measurable and more reproducible in diagnosis and follow-up, while adding a necessary laboratory foundation for a treatment era that is taking shape.

References

  1. Roche
  2. Roche Diagnostics
  3. Clinical Lab Products
  4. MarketScreener / S&P Capital IQ